TW200524585A - Human β-defensin secretion promoter - Google Patents
Human β-defensin secretion promoter Download PDFInfo
- Publication number
- TW200524585A TW200524585A TW093128401A TW93128401A TW200524585A TW 200524585 A TW200524585 A TW 200524585A TW 093128401 A TW093128401 A TW 093128401A TW 93128401 A TW93128401 A TW 93128401A TW 200524585 A TW200524585 A TW 200524585A
- Authority
- TW
- Taiwan
- Prior art keywords
- human
- acid
- defensin
- secretion
- defensin secretion
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 180
- 230000028327 secretion Effects 0.000 title claims abstract description 143
- 102000012265 beta-defensin Human genes 0.000 title abstract description 8
- 108050002883 beta-defensin Proteins 0.000 title abstract description 8
- 150000007524 organic acids Chemical class 0.000 claims abstract description 77
- 230000001737 promoting effect Effects 0.000 claims abstract description 57
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 108010002069 Defensins Proteins 0.000 claims description 136
- 102000000541 Defensins Human genes 0.000 claims description 135
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 36
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 101710178510 Defensin-2 Proteins 0.000 claims description 25
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 20
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 20
- 239000001630 malic acid Substances 0.000 claims description 20
- 235000011090 malic acid Nutrition 0.000 claims description 20
- 229940093915 gynecological organic acid Drugs 0.000 claims description 17
- 235000005985 organic acids Nutrition 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 16
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 16
- 235000015165 citric acid Nutrition 0.000 claims description 15
- 239000001530 fumaric acid Substances 0.000 claims description 15
- 235000011087 fumaric acid Nutrition 0.000 claims description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 13
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 12
- 235000011054 acetic acid Nutrition 0.000 claims description 12
- 239000011975 tartaric acid Substances 0.000 claims description 12
- 235000002906 tartaric acid Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 10
- 235000014655 lactic acid Nutrition 0.000 claims description 10
- 239000004575 stone Substances 0.000 claims description 10
- 239000001361 adipic acid Substances 0.000 claims description 8
- 235000011037 adipic acid Nutrition 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 7
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 7
- 235000013985 cinnamic acid Nutrition 0.000 claims description 7
- 229930016911 cinnamic acid Natural products 0.000 claims description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 235000011044 succinic acid Nutrition 0.000 claims description 4
- 239000001384 succinic acid Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 16
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 10
- 102000049262 human DEFB4A Human genes 0.000 abstract description 3
- 210000003296 saliva Anatomy 0.000 description 42
- 210000000214 mouth Anatomy 0.000 description 41
- 239000003814 drug Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 238000007429 general method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 229960001367 tartaric acid Drugs 0.000 description 8
- 102100038326 Beta-defensin 4A Human genes 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- 108010034266 theta-defensin Proteins 0.000 description 7
- ZKIAWZPHVZQYMG-QYJCGYSGSA-N θ-defensin Chemical compound O=C([C@@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CCCNC(N)=N)C(=O)N1)=O)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)[C@@H](C)CC)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]2CSSC1 ZKIAWZPHVZQYMG-QYJCGYSGSA-N 0.000 description 7
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 235000015218 chewing gum Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000008260 defense mechanism Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- -1 skin astringent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- 102100029790 Defensin-6 Human genes 0.000 description 3
- 101710178511 Defensin-6 Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000021185 dessert Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000003631 expected effect Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100021420 Defensin-5 Human genes 0.000 description 2
- 101710178517 Defensin-5 Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003444 succinic acids Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- ADWJKLSRYGGKHB-CATILVRHSA-N θ-defensin 2 Chemical compound O=C([C@@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(N[C@H]3CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)[C@@H](C)CC)N[C@@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H]2CSSC1 ADWJKLSRYGGKHB-CATILVRHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 101710178508 Defensin 3 Proteins 0.000 description 1
- 101710178505 Defensin-1 Proteins 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- KKNIUBFRGPFELP-UHFFFAOYSA-N secretolin Chemical compound N=1C=CNC=1CC(N)C(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NCC(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)C(C)O)CC1=CC=CC=C1 KKNIUBFRGPFELP-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- XMWGSPLTTNCSMB-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;chloride Chemical compound [Na+].[Cl-].OC(=O)CC(O)(C(O)=O)CC(O)=O XMWGSPLTTNCSMB-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GNKIAXMTFIKWLN-RVBNWZHFSA-N θ-defensin 3 Chemical compound C([C@@H]1NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CSSC[C@@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N3)[C@@H](C)O)=O)NC(=O)[C@H]([C@@H](C)CC)NC1=O)C(=O)N[C@H](C(N2)=O)[C@@H](C)CC)C1=CC=CC=C1 GNKIAXMTFIKWLN-RVBNWZHFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- General Preparation And Processing Of Foods (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200524585 九、發明說明: 【發明所屬之技術領域】 本發明是有關於可促進y5防禦素分泌之/3防禦素分泌促 進劑。又,本發明是有關於促進/3防禦素分泌之方法。 5【先前技術】 從以前就已知,在植物、昆蟲、兩棲類、哺乳類等當中存 在有活體内之抗菌物質(抗菌肽)作為與生倶來之活體防禦機 構,稱之為天然免疫,負責局部區域之感染防禦。在人類身上 已知之抗菌肽之一種之防禦素,對細菌、真菌、原蟲、病毒等 10 具有抗菌活性,而與活體内各種活體防禦機構相關連。 顯現於皮膚、肺、氣管、腎臟、生殖器等黏膜上皮之防禦 素,為人知的有/5防禦素。現在,人類/3防禦素已有6種(人 類/5防禦素-1、人類/5防禦素-2、人類Θ防禦素-3、人類冷防 禦素-4、人類0防禦素-5及人類点防禦素-6)已被單離且其構 15 造亦已確定。特別是人類yS防禦素-6,已清楚得知其在皮膚、 肺、氣管及口腔黏膜中尤其強烈地顯現出可在細菌感染或炎症 性細胞介素刺激下顯現衍生這種特徵(參考富田哲治等、「作 為活體防禦機構之防禦素」、曰本老年醫學會雜誌、2001年、 第18卷、第4號、第440-443頁),同時有報告指出其與肺炎 20 等氣管感染症或炎症有著密切關係。 又,近年,也有報告指出,/5防禦素不僅關係到局部之感 染防禦,甚至也藉由使樹狀細胞、T淋巴球、單核白血球等細 胞趨化而與後天性免疫有所關聯。(參考Yang, D·,Chertov, 0·, Bykovskaia, S.N. et al·, ί6 β -Defensins : linking innate and 200524585
Adaptive immunity through dendritic and T cell CCR6’’,Science, 1999,vol.286、p.525 ; Territo, M.C·,Ganz, T·,Selsted,M.E. et al., “Monocyto- chemotactic activity of defensins from human neutrophils’’,J· Clin. Invest·,1989, vol.84, p.2017 ; Lillard,J.W·, 5 Jr·, Boyaka,P.N·,Chertov O. et al·, “Mechanisms for induction of acquired host immunity by neutrophil peptide defensins", Proc. Natl. Acad. Sci. U.S.A·,1999,vol.96,p.651 ;長岡功等、 「Defensin在感染防禦與免疫應答之角色」、臨床免疫、2000 年、第33卷、第577頁)。 10 目前為止,已知炎症性細胞介素或脂多醣具有促進人類/3 防禦素分泌之作用。然而,關於人類/5防禦素之產生、分泌之 機制,仍未能充分清楚解釋,且除上述物質以外,亦未知可促 進人類yS防禦素分泌之方法機制。 【發明内容】 15 因此,本發明之目的係提供可促進人類/5防禦素分泌之冷 防禦素分泌促進劑。又,本發明之目的在於提供可以外用劑、 内用劑、食品等各種型態來使用之人類冷防禦素分泌促進劑。 又,本發明之目的是提供可有效促進人類々防禦素分泌之 方法。 20 本發明人為了解決上述課題而專心研討,結果發現,有機 酸具有可促進人類/5防禦素分泌之作用。本發明即是以該發現 為基礎再經過反覆研究而開發者。 亦即,本發明是以下揭示之人類Θ防禦素分泌促進劑: 1 · 一種人類/5防絮素分泌促進劑,係以有機酸為有效成分。 200524585 2.如第1項之人類/3防禦素分泌促進劑,其中前述有機酸 為選自於由延胡索酸、蘋果酸、檸檬酸、抗壞血酸、乳酸、醋 酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥珀酸構成之群之至 少一種。 5 3.如第1項之人類/3防禦素分泌促進劑,其中前述有機酸 為選自於由延胡索酸、蘋果酸、擰檬酸及酒石酸構成之群之至 少一種。
4.如第1項之人類/3防禦素分泌促進劑,其中作為分泌促 進對象之人類/5防禦素為人類/3防禦素-2。 10 5.如第1項之人類/3防禦素分泌促進劑,係使用於口唇部 或口腔内。 6. —種人類/3防禦素分泌促進用之外用組成物,含有第1~4 項中任一項之人類点防禦素分泌促進劑。 7. —種人類冷防禦素分泌促進用之内用組成物,含有第1〜4 15 項中任一項之人類/3防禦素分泌促進劑。
8. —種人類yS防禦素分泌促進用之食品,含有第1〜4項中 任一項之人類0防禦素分泌促進劑。 又,本發明是以下揭示之人類Θ防禦素分泌促進方法: 9. 一種人類Θ防禦素分泌促進方法,係對對象投予有效量 20 之有機酸或使對象攝取有效量之有機酸。 10. 如第9項之人類/3防禦素分泌促進方法,其中前述有機 酸為選自於由延胡索酸、蘋果酸、檸檬酸、抗壞血酸、乳酸、 醋酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥珀酸構成之群之 至少一種。 7 200524585 11. 如第9項之人類yS防禦素分泌促進方法,其中前述有機 酸為選自於由延胡索酸、蘋果酸、檸檬酸及酒石酸構成之群之 至少一種。 12. 如第9項之人類/5防禦素分泌促進方法,其中作為分泌 5 促進對象之人類yS防禦素為人類0防禦素-2。 13. 如第9項之人類/3防禦素分泌促進方法,係在口唇部或 口腔内促進人類Θ防禦素分泌。 14. 如第9項之人類石防禦素分泌促進方法,係使用第1〜5 項中任一項之人類点防禦素分泌促進劑作為前述有機酸。 10 15.如第9項之人類冷防禦素分泌促進方法,係使用第6項 之内用組成物作為前述有機酸。 16. 如第9項之人類冷防禦素分泌促進方法,係使用第7項 之食品作為前述有機酸。 17. 如第9項之人類冷防禦素分泌促進方法,係使用第8 15 項之外用組成物作為前述有機酸。 又,本發明是以下使用態樣: 18. —種有機酸之用途,係用以製造人類防禦素分泌促進 劑。 19. 一種有機酸之用途,係用以製造人類/3防禦素分泌促進 20 用内用組成物。 20. —種有機酸之用途,係用以製造人類/5防禦素分泌促進 用食品。 21. —種有機酸之用途,係用以製造人類yS防禦素分泌促進 用外用組成物。 200524585 22.—種有機酸之用途,係用以促進人類yS防禦素之分泌。 圖式簡單說明 第1圖是顯示試驗例1中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類/5防禦素-2之量(ng/min)之圖。 5 第2圖是顯示試驗例2中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類冷防禦素-2之量(ng/min)之圖。 第3圖是顯示試驗例3中,於口腔内使用各種量之蘋果酸 時,唾液中業經促進分泌之人類冷防禦素-2之量(ng/min)之 圖。 10【實施方式】 用以實施發明之形態 (1)人類yS防禦素分泌促進劑 本發明之人類点防禦素分泌促進劑中,作為分泌促進對象 之人類/5防禦素中,包含了人類冷防禦素-1、人類/5防禦素-2、 15 人類/5防禦素-3、人類/3防禦素-4、人類;3防禦素-5及人類冷 防禦素-6任一種。其中,尤其可有效促進人類占防禦素-2之分 泌,因此成為最適當之分泌促進對象。 本發明之Θ防禦素分泌促進劑之有效成分為有機酸。本發 明中所使用之有機酸,只要是藥學上、香粧學上或食品衛生上 20 可容許者,皆無特別限制。本發明所使用之有機酸之一例,可 舉蟻酸、醋酸、丙酸、酪酸、纈草酸、己酸、辛酸、癸酸、月 桂酸、肉莖蔻酸、棕櫚酸、硬脂酸、丙烯酸、丙醯酸、桂皮酸、 咖啡酸等單羧酸;草酸、丙二酸、琥珀酸、麩酸、己二酸、庚 二酸、延胡索酸、順丁稀二酸、苯二甲酸、異苯二甲酸、對苯 200524585 二甲酸等二羧酸;麩胺酸、天冬胺酸等胺基酸;乙二醇酸、雜 果酸、酒石酸、異酒石酸、檸檬酸、異檸檬酸、乳酸、羥丙稀 酸、α -羥酪酸、丙三醇酸、羥基丙二酸、水楊酸、五倍孑酸、 托品酸、抗壞血酸、葡糖酸等羥酸;葉酸;泛酸、菸鹼酸’ 5 及其他糖衍生物等之有機酸。其中又以延胡索酸、蘋果酸、 檸檬酸、抗壞血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、 麩胺酸及琥珀酸為佳,更以延胡索酸、蘋果酸、檸檬酸及酒石 酸為佳。這些有機酸可單獨使用1種,或任意組合2種以上來 使用。又,本發明中,有效成分除上述有機酸外,還可使用藥 10學上、香粧學上或食品衛生上可容許之上述有機酸之鹽,或使 其鹽與上述有機酸結合。 又,上述有機酸可不需使用精製者,只要含有上述有 作為成分之-者’即可作為本發明之人類彡㈣素分泌促 之有效成分來使用。 15 20
本發明之人類㈣絮素分泌促進劑可以是由上述有 分形成者,而除上財效齡外1可含«他食品衛生 樂學上或香粧學上可容許之基劑1體或添加物等其 本發明之人類万防禦素分泌促進劑之適用對象 _,可以是活體内之任〜部位或纟颂。從較優1之二類: ^素之分泌促進這個觀點來看,畠 ^ 1 ”、口腔内、咽頭、眼睛、生:Γ、肛門部、氣管内 較適宜之對象。其中,在口唇部及化器官内: 促進作用特別優異,因此口唇部及二=⑽素: 禦素分泌促進劑之最適宜之適用對象:。為本·明之人類‘ 10 200524585 本發明之人類沒防禦素分泌促進劑可混合於食品、内用醫 藥品、内用醫藥部外品等,作為人類冷防禦素分泌促進用之食 品或内用組成物來使用。又,本發明之人類万防禦素分泌促進 劑,可混合於外用醫藥品、外用醫藥部外品、香粧品、外用品 5 (綷創嘗)等,作為人類点防禦素分泌促進用之外用組成物來 使用。 含有本發明之人類石防禦素分泌促進劑之人類石防禦素 分泌促進用外用組成物之調製,除上述有效成分外,還可混合 藥學上或香粧學上可容許之基劑或載體,調製成所希望之形態 10即可。又,該外用組成物中,在不損壞本發明之效果之範圍内, 可混合各種界面活性劑、色素(染料、顏料)、香料、防腐劑、 救菌劑(抗菌劑)、增稠劑、抗氧化劑、金屬堵劑、清涼化劑、 防臭劑、pH調整劑等各種添加劑。又,亦可因應需要,添加保 …、S]各外線及收劑、紫外線漫射劑、維他命類、植物精華液、 皮膚收斂^、抗炎症劑(消炎劑)、美白劑、細胞賦活劑、血 &擴張劑、血行促進劑、抗生素劑等可混合於外用劑之眾所周 知之藥效成分。 上述外用組成物,只要可使用於皮膚或黏膜,其形狀並無 2〇寺別限制例如可舉液狀、乳液狀、粉末狀、懸浮液狀、霜狀、 車人用狀、幕斯狀、膠狀、抹醬狀、糊狀、床狀、片狀、噴霧狀、 嘴淋狀、濃_、面膜劑、貼附劑等形狀。又,上述外用组成 物之形狀可因應投予對象部位來適宜設定。 、 又上述外用組成物只要以發揮人類y?防禦素之分泌 作用為限度,亦& 乃了為具有人類防禦素分泌促進作用以外之作 200524585 用之外用組成物、具體來說,可舉創傷治癒劑、輕拭劑、清淨 (例士洗顏料、洗面乳、身體洗淨料等)、基礎化妝料(例 如乳液、乳霜、化妝水、油及面膜等)、刷牙劑、洗口劑、口 中清涼劑、口中用貼附劑等形態之外用組成物。尤其是從適用 於口腔内而可發揮人類錄紫素分泌促進作用之觀點來看,以 口中用貼附劑、刷牙劑、洗口劑或口中清涼劑之形態為佳。 又,上述外用組成物亦可為淀腸製劑、點眼劑、點鼻劑等 形態。又’使«散性有賊作為人_防㈣分泌促進劑之 有效成分時’藉由使有效成分揮發(蒸發)並吸取,亦可適用 於鼻腔内、口腔内或支氣管内。以這種形態來使用之方法,可 舉例如將δ有有效成分之水>谷液加熱等,吸取所得到之蒸氣這 種方法。亦可以如此使有效成分蒸發來使用之形態調製上述外 用組成物。調製為這種形態時,上述外用組成物可因應需要 藉由含有芳香成分’作為芳香液來使用。作為人類万防紫素分 15
泌促進劑之有效成分來使用之蒸散性有機酸可舉例如醋酸、丙 酸、蟻酸、酷酸、線草酸等。
上述人類Θ防禦素分泌促進用之外用組成物中之上述人類 冷防禦素分泌促進劑之混合比例,可因應該組成物之形態、有 效成分之種類、對象者之年齡或性別、所期待之效果等來適宜 20 地設定。例如,相對於上述外用組成物之總重量,上述人類冷 防素分泌促進劑之有效成分之比例可舉以總量〇·〇〇 1重量% 以上為佳,又以0·005〜99重量%為佳,又以0·01〜99重量%更佳。 本發明之人類々防禦素分泌促進劑藉由使用於皮膚或黏 膜,可發揮人類/5防禦素分泌促進作用。使用該人類万防禦素 12 200524585 分泌促進劑之量及次數,可因應有效成分之種類或濃度、使用 者之年齡或性別、使用形態、所期待之程度等來適宜地設定。 例如,以一日1~10次之程度,於皮膚或黏膜使用人類/3防禦素 分泌促進劑之有效成分O.lmg以上,又以0.5〜lOOOOmg為佳。 5 又,調製含有本發明之人類防禦素分泌促進劑之人類石
防禦素分泌促進作用之食品時,在一般之食品製造中,以上述 有效成分為成分之一混合於食品(包含飲料)中即可。又,人 類石防禦素分泌促進用食品中,可適當含有食品衛生上可容許 之各種食品添加物。 10 上述食品可舉例如特定保健用食品、營養補助食品、病患
用食品等。更具體來說,可例舉飲料(碳酸飲料、清涼飲料、 乳飲料、酒精飲料、果汁飲料、茶類、營養飲料等)、粉末飲 料(粉末果汁、粉末湯等)、點心類(口香糖、糖果、餅乾、 膠質點心、仙貝、比斯吉、果凍、牛奶糖、擰檬劑糖、可食性 15 片材、可食性薄片、喉鍵:等)、口中清涼劑(口香糖、始、膠 質點心、可食性片材、可食性薄片、喉錠等)、乳製品(乳酪、 優格等)、趣包、麵類、五榖、調味料(醬汁、調味汁等)等。 從促進口腔内人類yS防禦素之分泌這個觀點來看,其中適宜的 可有口香糖、膠質點心、檸檬劑、糖果、可食性片材及可食性 20 薄片。 上述人類/3防禦素分泌促進用食品中,所混合之人類/3防 禦素分泌促進劑之比例,可因應有效成分之種類、對象者之年 齡、性別、所期待之效果等來適宜地設定。例如,相對於上述 食品之總重量,上述人類yS防禦素分泌促進劑之有效成分之比 13 200524585 例可舉以總量0.01重量%以上為佳,又以〇·〇2〜100重量%為佳, 又以0.05〜100重量%更佳。 關於上述人類/3防禦素分泌促進用食品一日之攝取量,可 因應有效成分之種類或濃度、使用者之年齡或性別、食品之形 5 態、所期待之效果,來適宜地設定促進人類/5防禦素分泌所需 要之有效量。例如,該食品一曰之攝取量,可舉人類石防禦素 刀/必促進劑之有效成分O.lmg以上,又以〇·5〜lOOOOmg之量為 佳。 又’調製含有本發明之人類/3防禦素分泌促進劑之人類万 1〇 防集P素分泌促進作用之内用醫藥品組成物或内用醫藥部外品 組成物時’除上述有效成分之外,再混合藥學上可容許之基劑 或載體,調製成所希望之形態即可。又,可因應需要任意配合 結合劑、崩解劑、滑澤劑、濕潤化劑、緩衝劑、保存劑、香料 等藥學上可容許之添加劑。 15 上述内用醫藥品組成物或内用醫藥部外品組成物之形態, 並無特別限制,不過宜為可在黏膜上、特別是口香内熔解者。 例如,可舉薄片劑、喉錠、咀嚼錠、粉劑、錠劑、顆粒劑、膠 /糖水劑等。其中,從可在口腔内轉這個觀點來看,以 舉薄片劑、喉旋及咀嚼旋為佳。 御關於上述内用醫藥品或内用醫藥部外品組成物中,人類冷 =素^促進劑之混合比例,可因應有效成分之種類、組成 定之=1象者之年齡或性別、所期待之效果等來適宜地設 總重量,相對於上述内用醫藥品或内用醫藥部外品組成物之 述人類/3防t素分泌促進劑之有效成分之比例為總 14 200524585 量〇.01重量%以上為佳,又以〇.02〜99重量%為佳,又以〇〇5~99 重量%更佳。 關於上述内用醫藥品或内用醫藥部外品組成物人類之一日 之投藥量,會隨著有效成分之種類或濃度、使用者之年齡或性 5別、組成物之形狀、投藥方法、所期待之程度等而不同,因此 ’ 不能統—規定。不過只要是可促進人類点防禦素分泌之有效量 P可例如’一日投藥卜10次’每—次之投藥量為人類/3防禦 素刀泌促進劑之有效成分0.lmg以上,又以0_5~10000mg之量為 佳。 籲 10 如W所述,有機酸具有促進人類/3防禦素分泌之作用。因 此’本發明更提供有機酸之用於製造人類防禦素分泌促進用 之外用組成物或内用組成物之用途。 (2)人類)S防禦素分泌促進方法 如前所述,有機酸可有效促進人類Θ防禦素之分泌。因此, 15本發明提供利用有機酸促進人類0防禦素之分泌之方法。 本發明之人類/3防禦素分泌促進方法’係藉由針對目的欲 _ 促進人類万防禦素分泌之身體部位以外用形態投予有機酸來 實施。又,本發明之人類/3防禦素分泌促進方法可藉由以内用 形態投予有機酸,或使對象攝取有機酸來實施。本發明之方法 · 2〇係藉由使用上述(1)之人類防禦素分泌促進劑、尤其是人 - 類yS防禦素分泌促進用之外用組成物、内用組成物或食品來實 施0 本發明方法中,被促進分泌之人類Θ防^素、使用之有機 酸、該有機酸之投藥量或投藥次數、作為分泌促進對象之身體 15 200524585 部位(或組織)等,如前(1)所記載。 藉由使用有機酸,可有效促進人類/3防禦素之分泌。因此, 本發明更是提供有機酸之用以促進人類/3防禦素分泌之用途。 (3)人類冷防禦素分泌促進方法-2 5 又,本發明人發現,藉由使口腔内環境暫時呈現酸性,即
可促進口腔内之人類/3防禦素分泌。依據該發現,本發明更提 供促進口腔内人類/3防禦素分泌之方法。藉該方法,欲促進人 類冷防禦素分泌,
口腔内環境暫時呈現酸性,具體來說使口腔内之pH保持在7 10 以下即可,又以6.2以下為佳。又,該方法中,使口腔内環境保 持酸性之時間,是促進人類yS防禦素分泌之有效時間即可。 又,該方法中,欲使口腔内環境成為酸性,例如只需在口腔内 投予前述有機酸即可。該方法之適當實施形態之一例,可舉在 口腔内投予前述人類防禦素分泌促進劑之方法。藉該方法, 15 可保持口腔内健康,因此,該方法對預防及緩和牙周病、口内 炎、齟齒、口臭等是有用的。 又,上述(1)之人類0防禦素分泌促進劑之用途、或上述 (2)之人類石防禦素分泌促進方法中,皮膚或黏膜上之pH條 件並無特別限制。 20 實施例 以下舉實施例及試驗例說明本發明,然而本發明並不受限 於這些實施例。又,以下,人類yS防禦素亦僅表記為hBD-2。 實施例1 口香糖 依據一般方法製造下述處方之口香糖。 16 200524585 混合量(重量%) 擰檬粉末 5.0 (擰檬粉末中含檸檬酸75重量% ) 口香糖基質 (主成分:醋酸乙烯) 22.0 木糖醇 35.0 麥芽糖醇 27.0 香料 適量 合計 100重 實施例2 擰檬劑糖果 依據一般方法製造下述處方之檸檬劑糖果 混合量(重量%) 蘋果酸 7.5 碳酸氫鈉 7.5 木糖醇 40.0 麥芽糖醇 30.0 玉米澱粉 15.0 合計 100重量% 實施例3 口中清涼旋(液狀) 依據一般方法製造下述處方之口中清涼錠 混合量(重量%) 乳酸 0.2 1-薄荷醇 1.0 乙醇 40.0 丙三醇 20.0 單月桂酸十丙三醇 〇·5 香料 0.1 精製水 殘量 合計 100重量% 實施例4 口中清涼錠(喉錠)
U
10 依據一般方法製造下述處方之口中清涼旋(喉鍵) 17 200524585 酒石酸 1 -薄荷醇 碳酸氫鈉 乳糖 蔗糖脂肪酸酯 風味劑 甘味劑 合計 混合量(重量%) 45 1 24 25 3 1 1 100重量% 實施例5 食品(喉錠) 依據一般方法製造下述處方之食品(喉錠)。 混合量(重量%)
抗壞血酸 乳糖 木糖醇 蔗糖脂肪酸酯 風味劑 合計 5.0 85.5 5.0 4.0 0.5 100重量% 實施例6 液體刷牙劑 依據一般方法製造下述處方之液體刷牙劑。
延胡索酸 1-薄荷醇 碳酸氫納 混合量(重量%) 45 1 24 乳糖 25 蔗糖脂肪酸酯 3 風味劑 甘味劑 1 合計 100重量% 10 實施例7 芳香液 依據一般方法製造下述處方之芳香液。 18 200524585 混合量(重量%) 精製水 54 無水乙醇 40 檸檬萃取 4 葡萄柚萃取 1 醋酸 1 香料 適量 合計 100重量% 實施例8 點鼻劑
依據一般方法製造下述處方之點鼻劑。 成分名 氯化納 檸檬酸 pH調整劑 精製水 合計 混合量(重量%) 0.9 1.0 適量 殘餘 100重量% 實施例9 點眼劑 依據一般方法製造下述處方之點眼劑。
成分名 氣化納 氯化鉀 黃素腺二核苷酸 透明質酸 檸檬酸 pH調整劑 精製水 合計 混合量(重量%) 0.9 0.1 0.05 0.1 1.0 適量 殘餘 100重量% 試驗例1 /3防禦素分泌促進確認試驗-1 10 為了評價各種有機酸之/3防禦素分泌促進效果,以健常人1 名為受驗者進行下述試驗。 19 200524585 藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入延胡索酸50mg, 保持1分鐘後,與分泌出之唾液一起回收。藉ELISA法,測定所 回收之唾液中之人類防禦素-2濃度,依據下記計算式,計算 5 出在1分鐘内藉該有機酸而分泌之人類/3防禦素-2之量。但是, 下記計算式中之唾液量(ml)係以唾液重量lg=唾液量lml,而 從業已回收之唾液之重量(g)算出。前述相同試驗,亦分別 利用抗壞血酸、檸檬酸、蘋果酸、乳酸、己二酸、醋酸及酒石 酸取代延胡索酸來進行。又,乳酸及醋酸之情況,係藉由在口 10 腔中置入業已在該有機酸50mg中添加水以調整全量為lg者,來 進行上述試驗。 計算式 [1分鐘被分泌之hBD-2之量(ng/min)]= {[唾液中之hBD-2濃度(ng/ml) ] X[唾液量(ml) ]}/[唾液回收時間(min)] 15 #唾液回收時間,在控制組為3分鐘,在投予有機酸後之情況為1分鐘。
所得到之結果顯示於第1圖。可清楚得知,藉由在口腔内適 用有機酸,而增加了唾液中所分泌之人類防禦素-2量。從該 結果,確認了有機酸具有促進活體内人類0防禦素-2之分泌之 作用,尤其在口腔内之人類/5防禦素-2之分泌促進作用上很優 20 異。 試驗例2 yS防禦素分泌促進確認試驗-2 為了評價各種有機酸之yS防禦素分泌促進效果,以健常人6 名為受驗者進行下述試驗。有機酸係使用檸檬酸、蘋果酸、延 胡索酸、L-麩胺酸、反桂皮酸、L ( + )-抗壞血酸、琥珀酸、 20 200524585 DL-酒石酸、己二酸、L-乳酸及醋酸。 藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入有機酸50mg, 保持1分鐘後,與分泌出之唾液一起回收。藉ELISA法,測定所 5 回收之唾液中之人類yS防禦素-2濃度,依據下記計算式,計算 出在1分鐘内藉該有機酸而分泌之人類卢防禦素-2之量。但是, 下記計算式中之唾液量(ml)係以唾液重量lg=唾液量lml,而 從業已回收之唾液之重量(g)算出。又,乳酸及醋酸之情況, 係藉由在口腔中置入業已在該有機酸50mg中添加水以調整全 10 量為lg者,來進行上述試驗。 計算式 [1分鐘被分泌之hBD-2之量(ng/min)]= {[唾液中之hBD-2濃度(ng/ml) ] X[唾液量(ml ) ]}/[唾液回收時間(min )] #唾液回收時間,在控制組為3分鐘,在投予有機酸後之情況為1分鐘。 15 所得到之結果顯示於第2圖。從該結果可清楚得知,與試驗 例1之結果同樣地,藉由在口腔内適用有機酸,而增加了唾液 中所分泌之人類万防禦素-2量。 試驗例3 0防禦素分泌促進確認試驗-3 (濃度依賴性) 為了評價有機酸之yS防禦素分泌促進效果與濃度依賴性之 20 關係,以健常人3名為受驗者進行下述試驗。 藉吐出法回收業已處於安靜之受驗者在3分鐘内所分泌之 唾液(以下記為控制組)。然後,於口腔内放入0.01重量%蘋果 酸水溶液lml (蘋果酸攝取量O.lmg)。保持1分鐘後,與分泌出 之唾液一起回收。藉ELISA法,測定所回收之唾液中之人類冷 21 200524585 防禦素-2濃度,依據下記計算式,計算出在1分鐘内藉攝取該蘋 果酸而分泌之人類yS防禦素-2之量。但是,下記計算式中之唾 液量(ml)係以唾液重量lg=唾液量lml,而從業已回收之唾液 之重量(g)算出。進一步,分別利用〇·〇5、0·1、0·2、0.5及1 5 重量%蘋果酸水溶液(攝取量0.5、1、2、5、10mg)進行。 計算式 [1分鐘被分泌之hBD-2之量(ng/min)]= {[唾液中之hBD-2濃度(ng/ml)] X[唾液量(ml)]}/[唾液回收時間(min)] #唾液回收時間,在控制組為3分鐘,在投予有機酸後之情況為1分鐘。 10 所得到之結果顯示於第3圖。從第3圖可清楚得知,唾液中 所分泌之人類/3防禦素-2量係蘋果酸水溶液之濃度依賴性而增 大。從該結果,確認了有機酸之人類/3防禦素-2分泌促進效果 具有濃度依賴性,即使為0.01%濃度(攝取量O.lmg),也具有 人類Θ防禦素-2分泌衍生效果。 15 產業上可利用性 人類/3防禦素因具備以下優異特性而為人所知:(a)由於 其自身具有抗菌性,因此可在短時間内發揮抗菌作用;(b)由 於在活體内分泌,因此對習知抗菌劑難以利用外用或内用形態 來投藥之部位,也可發揮優異抗菌作用;(c)使樹狀細胞或記 20 憶T淋巴球趨化(chemotaxis )(亦即,動員免疫負責細胞而與 後天免疫有關)。 本發明之人類0防禦素分泌促進劑可在適用之部位促進/3 防禦素之分泌,尤其是促進人類0防禦素-2之分泌。因此,藉 本發明之人類/3防禦素分泌促進劑,可促進yS防禦素之分泌, 22 200524585 增強活體内之抗菌作用或免疫作用,藉此,可提高活體之防禦 機制。因此,本發明之人類yS防禦素分泌促進劑對預防或緩和 起因於細菌、真菌、病毒、原蟲感染所造成之症狀上很有效。 尤其是可有效利用在預防異位性皮膚炎之二次感染、預防面皰 5 粉刺、防止口臭、防止足臭、預防剃鬚或脫毛後之二次感染、 預防尿布疹之二次感染、預防痱子之二次感染、預防燙傷之二 次感染、預防因使用類固醇造成之易感染性等護膚上。又,對 起因於細菌、真菌、病毒、原蟲感染所造成之皮膚粗糙、皮膚 乾燥、富貴手等護膚上也有效。 10 又,本發明之人類yS防禦素分泌促進劑,可期待其依據人 類冷防禦素分泌促進作用所帶來的藥理效果。因此,本發明之 人類/5防禦素分泌促進劑,例如投藥於眼内時,可預防或治療 病毒性結膜炎、細菌性結膜炎、麥粒腫等;投藥於鼻腔内或咽 頭時,可預防或治療感冒、流行性感冒等;投藥於鼻腔内時, 15 可預防或治療鼻炎、膿性鼻漏、副鼻腔炎等;使用於口腔内時, 可預防或治療牙周病、口内炎、齟齒等,使用於口唇部時,可 預防或治療單純泡疹等;使用於皮膚時,可預防香港腳、治療 泡療、疲贅、傳染性軟屬腫、水痘、性器官泡療病毒感染症、 念珠菌症、帶狀泡疹、單純泡疹、面皰、異位性皮膚炎、創傷 20 等;使用於其他部位時,可作為肺炎、胃炎、腫瘤、後天性免 疫缺乏症、錐蟲病等疾病之預防或治療劑。這些疾病當中,作 為與細菌、真菌、病毒、原蟲等有關之疾病之預防或治療劑尤 其有用。 又,本發明之人類yS防禦素分泌促進劑,在口腔内及口唇 23 200524585 部可發揮進一步的/3防禦素分泌促進作用,因此作為牙周病、 口内炎、齟齒、口臭、單純泡疹等之預防或治療劑特別有效。 因此,本發明之人類石防禦素分泌促進劑可適當使用在用以保 持健康口腔環境之護膚製品。 5【圖式簡單說明】 第1圖是顯示試驗例1中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類冷防禦素-2之量(ng/min)之圖。 第2圖是顯示試驗例2中,於口腔内使用各有機酸時,唾 液中業經促進分泌之人類Θ防禦素-2之量(ng/min)之圖。 10 第3圖是顯示試驗例3中,於口腔内使用各種量之蘋果酸 時,唾液中業經促進分泌之人類/5防禦素-2之量(ng/min)之 圖。 【主要元件符號說明】 無 24
Claims (1)
- 200524585 十、申請專利範圍: 1. 一種人類yS防禦素分泌促進劑,係以有機酸為有效成分。 2. 如申請專利範圍第1項之人類/5防禦素分泌促進劑,其中前 述有機酸為選自於由延胡索酸、蘋果酸、擰檬酸、抗壞血 5 酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、麩胺酸及琥 珀酸構成之群之至少一種。 3. 如申請專利範圍第1項之人類/3防禦素分泌促進劑,其中前 述有機酸為選自於由延胡索酸、蘋果酸、擰檬酸及酒石酸 構成之群之至少一種。 10 4.如申請專利範圍第1項之人類/3防禦素分泌促進劑,其中作 為分泌促進對象之人類防禦素為人類万防禦素-2。 5. 如申請專利範圍第1項之人類/3防禦素分泌促進劑,係使用 於口唇部或口腔内。 6. —種人類卢防禦素分泌促進用之外用組成物,含有申請專 15 利範圍第1〜4項中任一項之人類卢防禦素分泌促進劑。 7. —種人類/3防禦素分泌促進用之内用組成物,含有申請專 利範圍第1〜4項中任一項之人類冷防禦素分泌促進劑。 8. 一種人類防禦素分泌促進用之食品,含有申請專利範圍 第1〜4項中任一項之人類yS防禦素分泌促進劑。 20 9. 一種人類/3防禦素分泌促進方法,係對對象投予有效量之 有機酸或使對象攝取有效量之有機酸。 10.如申請專利範圍第9項之人類/3防禦素分泌促進方法,其中 前述有機酸為選自於由延胡索酸、蘋果酸、檸檬酸、抗壞 血酸、乳酸、醋酸、己二酸、酒石酸、桂皮酸、麩胺酸及 25 200524585 琥珀酸構成之群之至少一種。 11.如申請專利範圍第9項之人類/3防禦素分泌促進方法,其中 前述有機酸為選自於由延胡索酸、蘋果酸、擰檬酸及酒石 酸構成之群之至少一種。 5 12.如申請專利範圍第9項之人類/3防禦素分泌促進方法,其中 作為分泌促進對象之人類/9防禦素為人類/5防禦素-2。 13. 如申請專利範圍第9項之人類石防禦素分泌促進方法,係在 口唇部或口腔内促進人類/3防禦素分泌。 14. 如申請專利範圍第9項之人類/3防禦素分泌促進方法,係使 10 用申請專利範圍第1〜5項中任一項之人類石防禦素分泌促 進劑作為前述有機酸。 15. 如申請專利範圍第9項之人類石防禦素分泌促進方法,係使 用申請專利範圍第6項之内用組成物作為前述有機酸。 16. 如申請專利範圍第9項之人類/3防禦素分泌促進方法,係使 15 用申請專利範圍第7項之食品作為前述有機酸。 17. 如申請專利範圍第9項之人類/3防禦素分泌促進方法,係使 用申請專利範圍第8項之外用組成物作為前述有機酸。 18. —種有機酸之用途,係用以製造人類yS防禦素分泌促進劑。 19. 一種有機酸之用途,係用以製造人類0防禦素分泌促進用 20 内用組成物。 20. —種有機酸之用途,係用以製造人類yS防禦素分泌促進用 食品。 21. —種有機酸之用途,係用以製造人類防禦素分泌促進用 外用組成物。 26 200524585 22· —種有機酸之用途,係用以促進人類/5防禦素之分泌。 27
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003328704 | 2003-09-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200524585A true TW200524585A (en) | 2005-08-01 |
TWI342773B TWI342773B (zh) | 2011-06-01 |
Family
ID=34372909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093128401A TW200524585A (en) | 2003-09-19 | 2004-09-20 | Human β-defensin secretion promoter |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070093416A1 (zh) |
EP (1) | EP1671629A4 (zh) |
JP (1) | JP4847756B2 (zh) |
KR (1) | KR20060076775A (zh) |
CN (1) | CN1852708B (zh) |
AU (1) | AU2004273738B2 (zh) |
BR (1) | BRPI0414543A (zh) |
CA (1) | CA2538760A1 (zh) |
HK (1) | HK1092057A1 (zh) |
TW (1) | TW200524585A (zh) |
WO (1) | WO2005027893A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008001800A1 (fr) | 2006-06-28 | 2008-01-03 | Otsuka Pharmaceutical Co., Ltd. | Inhibiteur de la dissolution de l'émail dentaire |
JPWO2008096730A1 (ja) * | 2007-02-09 | 2010-05-20 | 国立大学法人名古屋大学 | 抗炎症剤及びその用途 |
JP2009007323A (ja) * | 2007-05-29 | 2009-01-15 | Earth Chem Corp Ltd | ウイルス不活化剤、ウイルス感染予防方法及びそのウイルス不活化剤をも収納し得る容器 |
JP5511183B2 (ja) * | 2007-12-28 | 2014-06-04 | アース製薬株式会社 | 有機酸による歯のエナメル質の溶解が阻害される口腔用組成物 |
US8076088B2 (en) * | 2008-02-22 | 2011-12-13 | Case Western Reserve University | Method of detecting human β-defensins |
KR101489638B1 (ko) * | 2008-04-01 | 2015-02-11 | (주)네오팜 | 인간유래 항균 펩타이드의 분비를 촉진하는 신규화합물, 그제조방법, 및 이를 유효성분으로 함유하는피부외용제조성물 |
CN101591672B (zh) * | 2009-05-22 | 2011-09-07 | 西北农林科技大学 | 一种包含hBD3乳腺特异性表达载体的重组牛胎儿成纤维细胞 |
GB0920846D0 (en) | 2009-11-27 | 2010-01-13 | Croda Int Plc | Defenin inducing agent |
NZ602909A (en) | 2010-04-15 | 2015-01-30 | Marinepolymer Tech Inc | Anti-bacterial applications of poly -n-acetylglucosamine nanofibers |
KR101257228B1 (ko) * | 2010-06-16 | 2013-04-29 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
SG187666A1 (en) | 2010-08-27 | 2013-03-28 | Neopharm Co Ltd | Novel compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient |
JP6144254B2 (ja) | 2011-04-15 | 2017-06-07 | マリン ポリマー テクノロジーズ,インコーポレーテッド | ポリ−n−アセチルグルコサミンナノファイバを用いた疾患の治療 |
JP6063191B2 (ja) * | 2011-09-27 | 2017-01-18 | 参天製薬株式会社 | ヒアルロン酸およびフラビンアデニンジヌクレオチドを組み合わせたことを特徴とする角膜上皮細胞死の抑制剤 |
US9532946B2 (en) * | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
KR20150118144A (ko) * | 2013-02-14 | 2015-10-21 | 라이온 가부시키가이샤 | 구강용 조성물 |
JP6209062B2 (ja) * | 2013-11-12 | 2017-10-04 | 株式会社ファンケル | 抗菌性ペプチドの分泌促進剤 |
EP3435765A1 (en) * | 2016-03-31 | 2019-02-06 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
JP2019510036A (ja) | 2016-03-31 | 2019-04-11 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティクス/プレバイオティクス有効成分を含む清浄剤組成物 |
CA3018865A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
AU2017365019A1 (en) | 2016-11-23 | 2019-07-11 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
KR102488864B1 (ko) * | 2016-11-25 | 2023-01-17 | (주)모아캠 | 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물 |
CN107918010A (zh) * | 2017-11-27 | 2018-04-17 | 陕西科技大学 | 一种高灵敏液晶型非标记免疫传感器检测人类β防御素‑2的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL58009A (en) * | 1978-08-14 | 1982-11-30 | Sterling Drug Inc | Process and compositions comprising glutaric acid for neutralizing or destroying viruses |
JPH03294227A (ja) * | 1990-04-13 | 1991-12-25 | Dai Ichi Seiyaku Co Ltd | 口腔用組成物 |
WO1992012952A1 (en) * | 1991-01-18 | 1992-08-06 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
US5260083A (en) * | 1992-03-25 | 1993-11-09 | The J. M. Smucker Company | Fruit spread and method of preparing same |
JP3207523B2 (ja) * | 1992-06-19 | 2001-09-10 | 明治乳業株式会社 | 肝障害患者に有効な組成物 |
CN1033421C (zh) * | 1992-12-09 | 1996-12-04 | 何名富 | 一种药物牙膏的制备方法 |
US5830487A (en) * | 1996-06-05 | 1998-11-03 | The Procter & Gamble Company | Anti-viral, anhydrous, and mild skin lotions for application to tissue paper products |
DE4439858A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung |
JP3241955B2 (ja) * | 1994-12-26 | 2001-12-25 | 花王株式会社 | 口腔用組成物 |
RO120038B1 (ro) * | 1995-02-28 | 2005-08-30 | U.S. Meds- Bulgaria Ltd. | Compoziţie pentru igiena, profilaxia şi tratamentul afecţiunilor cavităţii bucale |
CN1229641A (zh) * | 1998-03-20 | 1999-09-29 | 湖北医科大学附属第二医院 | 假牙清洁剂 |
US6469066B1 (en) * | 1998-12-18 | 2002-10-22 | Palladin Healthcare International, Ltd. | Composition for pain mediation and apparatus and method of use thereof |
JP2001089385A (ja) * | 1999-09-22 | 2001-04-03 | Kobayashi Pharmaceut Co Ltd | 抗う蝕剤 |
PL199782B1 (pl) * | 1999-10-19 | 2008-10-31 | Procter & Gamble | Środek do nosa do zapobiegania i leczenia wirusowego przeziębienia i grypy |
WO2001068085A1 (en) * | 2000-03-15 | 2001-09-20 | Genaera Corporation | A method for stimulation of defensin production |
JP2002114704A (ja) * | 2000-09-29 | 2002-04-16 | Morinaga & Co Ltd | 抗菌剤 |
JP2003000262A (ja) * | 2001-06-22 | 2003-01-07 | Morinaga & Co Ltd | ほ乳類抗菌ペプチドの発現誘導及び/又は増強組成物、該組成物を含有する飲食品、医薬品及び医薬部外品 |
JP2003116486A (ja) * | 2001-08-09 | 2003-04-22 | Meiji Milk Prod Co Ltd | 食後の血糖上昇抑制作用を有する食品組成物 |
JP2003095938A (ja) * | 2001-09-21 | 2003-04-03 | Masami Moriyama | 抗菌ペプチド分泌誘発剤 |
US20040063123A1 (en) * | 2002-03-05 | 2004-04-01 | Yoshihiro Abiko | Method of collecting data for estimation of susceptibility to periodontal disease |
FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
JP4554150B2 (ja) * | 2002-11-28 | 2010-09-29 | 雅美 森山 | 薬剤耐性菌による感染症治療剤 |
JP4683844B2 (ja) * | 2003-02-10 | 2011-05-18 | 雅美 森山 | インフルエンザウイルス感染予防剤 |
US7041311B2 (en) * | 2003-02-28 | 2006-05-09 | International Flavors & Fragrances Inc. | Preparation for saliva flow |
-
2004
- 2004-09-17 BR BRPI0414543-7A patent/BRPI0414543A/pt not_active IP Right Cessation
- 2004-09-17 US US10/572,204 patent/US20070093416A1/en not_active Abandoned
- 2004-09-17 KR KR1020067005330A patent/KR20060076775A/ko not_active Application Discontinuation
- 2004-09-17 AU AU2004273738A patent/AU2004273738B2/en not_active Ceased
- 2004-09-17 CA CA002538760A patent/CA2538760A1/en not_active Abandoned
- 2004-09-17 EP EP04773408A patent/EP1671629A4/en not_active Withdrawn
- 2004-09-17 WO PCT/JP2004/014024 patent/WO2005027893A1/ja active Application Filing
- 2004-09-17 CN CN2004800270414A patent/CN1852708B/zh not_active Expired - Fee Related
- 2004-09-17 JP JP2005514130A patent/JP4847756B2/ja active Active
- 2004-09-20 TW TW093128401A patent/TW200524585A/zh not_active IP Right Cessation
-
2006
- 2006-11-20 HK HK06112727.9A patent/HK1092057A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0414543A (pt) | 2006-11-07 |
TWI342773B (zh) | 2011-06-01 |
CA2538760A1 (en) | 2005-03-31 |
AU2004273738B2 (en) | 2011-02-03 |
US20070093416A1 (en) | 2007-04-26 |
KR20060076775A (ko) | 2006-07-04 |
WO2005027893A1 (ja) | 2005-03-31 |
JPWO2005027893A1 (ja) | 2006-11-24 |
AU2004273738A1 (en) | 2005-03-31 |
EP1671629A1 (en) | 2006-06-21 |
CN1852708A (zh) | 2006-10-25 |
HK1092057A1 (en) | 2007-02-02 |
EP1671629A4 (en) | 2008-11-26 |
JP4847756B2 (ja) | 2011-12-28 |
CN1852708B (zh) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4847756B2 (ja) | ヒトβディフェンシン分泌促進剤 | |
TW200533333A (en) | Human beta-defensin production accelerator | |
CN108670889A (zh) | 一种防治口腔溃疡的牙膏及其制备方法 | |
RU2762754C2 (ru) | Композиция для применения в предупреждении и/или лечении индуцированного онкологическим лечением мукозита полости рта и желудочно-кишечного тракта | |
JP5053535B2 (ja) | 寝つきまたは寝起き改善用経口剤 | |
JPH08325156A (ja) | ステビオール配糖体含有皮膚外用剤及び飲食品 | |
EP1818053A1 (en) | Preventive/remedy for allergic diseases | |
JP2003081824A (ja) | 高血圧症予防・改善・治療剤 | |
JPH06506682A (ja) | 上部胃腸管症状を治療するための内服医薬組成物 | |
JP6600124B2 (ja) | 菓子 | |
JP5328158B2 (ja) | カンジダ菌感染に基づく疾患の予防又は改善剤及び経口組成物 | |
JP2023038290A (ja) | ロイシン誘導体、それを含む組成物及びその用途 | |
JP5511183B2 (ja) | 有機酸による歯のエナメル質の溶解が阻害される口腔用組成物 | |
CN108403544A (zh) | 一种儿童口腔护理组合物及其制备方法 | |
JP6840647B2 (ja) | 液体組成物、その白濁改善剤、臭気改善剤、及び製造方法 | |
JP6864964B2 (ja) | 経口睡眠改善剤 | |
RU2777153C1 (ru) | Композиция для ухода за полостью рта для пациентов с метаболическими нарушениями | |
JPH02193926A (ja) | 胃腸薬 | |
WO2016195089A1 (ja) | 唾液分泌促進剤、口腔乾燥抑制剤及び口腔内うるおい付与剤、及び組成物 | |
AU2021225354B2 (en) | Composition for the prevention and treatment of dysbiosis | |
US20040192587A9 (en) | Zinc formulations as a prophylactic treatment for the common cold | |
WO2009031922A1 (en) | Tablet for prophylaxis and treatment of dental and periodontium diseases | |
JP2002201135A (ja) | ラクツロースを含有する上腹部用組成物 | |
WO2006003750A1 (ja) | 炎症予防・抗炎症剤、医薬品、飲食品及び香粧品 | |
WO2022138565A1 (ja) | 抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |